269
Views
15
CrossRef citations to date
0
Altmetric
Heliobacter Pylori

Novel combination therapy for the eradication of Helicobacter pylori infection in a mouse model

, , , , &
Pages 1424-1430 | Received 08 Feb 2010, Accepted 29 Jun 2010, Published online: 26 Jul 2010
 

Abstract

Objective. To investigate the combination therapy, consisting of hyperimmune bovine colostrum, N-acetyl cysteine, zinc and amoxicillin on the eradication of Helicobacter pylori in a mouse model. Material and methods. C57BL/6 female mice (6 weeks of age) were inoculated with 0.1 ml of 1 × 109 H. pylori via a single oro-gastric gavage and were left infected for 4 weeks. Mice (n = 9/group) were randomly allocated to receive by oral gavage (0.1 ml) HNZ (hyperimmune bovine colostrum + N-acetyl cysteine + zinc), HNZA (HNZ + amoxicillin; A), HNZA2 (2× amoxicillin; A2), HNZA5 (5× amoxicillin; A5), triple therapy (TT) or saline twice daily for 10 days. Bacterial load was assessed by culture. Gastric emptying was assessed by 13C-octanoic acid breath test. Results. Mice receiving HNZ, HNZA, and HNZA2 have a 22%, 44% and 67% eradication rate, respectively. Eradication rate was 100% with HNZA5, TT and those animals receiving A5 alone. In H. pylori infected mice there was an increased gastric emptying time by 7.9, 3.7, 10.1 and 7.7 min for the TT, HNZ, HNZA2, and HNZA5, respectively, compared to saline. Conclusions. HNZ with the addition of a high dose of amoxicillin is effective at eradicating H. pylori in vivo as HNZA1 and HNZA2 did not give raise to eradication. The potency of the novel anti-H. pylori combination therapy may be due to the delayed gastric emptying.

Acknowledgements

The authors thank the National Health and Medical Research Council for their support of the Industry Fellowship for Dr CD Tran. Dr CD Tran was also a recipient of the MS McLeod Post-Doctoral Fellowship obtained from the Women's and Children's Hospital Foundation. The authors thank Ms Rosa Katsikeros for the proofreading of this manuscript. The anti-H. pylori combination therapy consisting of hyperimmune bovine colostrum, N-acetyl cysteine, and amoxicillin is a patent of Nidor Pty. Ltd.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.